Hematologic Oncology | Specialty

Selecting the Optimal Frontline Therapy in CLL

March 31st 2018

Evolution of Biological Understandings in CLL

March 31st 2018

Impact of Prognostic Factors on Clinical Decisions in CLL

March 31st 2018

Other Prognostic Factors in Chronic Lymphocytic Leukemia

March 31st 2018

TP53 and Deletion 17p as Prognostic Factors in CLL

March 31st 2018

Combined Radiation Therapy and Checkpoint Inhibition in Lymphoma: A Case Report and Brief Review

March 31st 2018

The emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.

Dr. Bachier Discusses Toxicities With Stem Cell Transplant

March 30th 2018

Carlos R. Bachier, MD, director, blood and marrow transplant research, Sarah Cannon Research Institute, discusses toxicities associated with stem cell transplant.

Dr. Skarbnik on the Role of Chemotherapy in CLL

March 30th 2018

Alan Skarbnik, MD, staff physician, Department of Bone Marrow Transplantation and Department of Lymphoma, John Theurer Cancer Center, discusses the use of chemotherapy in patients with chronic lymphocytic leukemia (CLL).

Dr. Moskowitz on the ALCANZA Trial in CTCL

March 30th 2018

Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses the data that led to the approval of brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL).

FDA Approves Blinatumomab for MRD+ ALL

March 29th 2018

The FDA has approved blinatumomab for the treatment of patients with minimal residual disease–positive B-cell precursor acute lymphoblastic leukemia.

Dr. Donnellan Discusses Trials in Hematologic Malignancies

March 28th 2018

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses ongoing trials in hematologic malignancies.

Dr. Winter Discusses the ZUMA-7 Trial in DLBCL

March 27th 2018

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the ZUMA-7 trial (NCT03391466) in diffuse large B-cell lymphoma (DLBCL).

Ponatinib Maintains Benefit in Chronic-Phase CML at 5 Years

March 22nd 2018

Ponatinib maintained deep, durable responses in heavily pretreated patients with chronic-phase chronic myeloid leukemia (CP-CML).

Dr. Donnellan on Combinations Under Investigation in Acute Leukemia

March 21st 2018

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses combinations under investigation in acute leukemia.

CLL Expert Explains Latest Treatment Developments in the Field

March 21st 2018

Neil E. Kay, MD, discusses the available options and sequencing challenges for patients with relapsed/refractory chronic lymphocytic leukemia, as well as next steps for advancing outcomes for this patient population.

FDA Approves Brentuximab Vedotin for Frontline Hodgkin Lymphoma

March 20th 2018

The FDA has approved brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma.

Dr. Flinn on FDA Approval of Frontline Brentuximab Vedotin With AVD in Hodgkin Lymphoma

March 20th 2018

Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of brentuximab vedotin (Adcetris) combined with Adriamycin, vinblastine, and dacarbazine (AVD) as a frontline treatment for patients with advanced classical Hodgkin lymphoma.

John Theurer Cancer Center First NJ Site Certified to offer CAR-T Cell Cancer Therapy

March 9th 2018

Breakthrough gene therapy for B-cell lymphoma now available at Hackensack University Medical Center.

Fostamatinib Active in Chronic Immune Thrombocytopenic Purpura

March 8th 2018

Fostamatinib resulted in clinically meaningful, ongoing platelet responses and a low rate of bleeding events in 43% of patients with chronic immune thrombocytopenic purpura with long-disease duration.

Dr. Laramore on Genetic Testing in Hematologic Cancers

March 8th 2018

Andrew Laramore, MD, Anatomic and Clinical Pathology, Diagnostic Pathology Services, discusses some of the known genes that are tested for in hematologic malignancies.